



## **Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference**

January 31, 2024

WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim 6<sup>th</sup> Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 pm EST.

A live webcast can be accessed under "Events & Presentations" in the Investors & Media section of the Xilio Therapeutics website at <https://ir.xiliotx.com/>. A replay of the webcast will be archived on the website for 30 days following the presentation.

### **About Xilio Therapeutics**

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary geographically precise solutions (GPS) platform to build a pipeline of novel, tumor-activated molecules, including antibodies, cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development. Learn more by visiting [www.xiliotx.com](http://www.xiliotx.com) and follow us on LinkedIn ([Xilio Therapeutics, Inc.](https://www.linkedin.com/company/xilio-therapeutics)).

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

### **Contacts:**

#### **Investors:**

Melissa Forst  
Argot Partners  
[Xilio@argotpartners.com](mailto:Xilio@argotpartners.com)

#### **Media:**

Dan Budwick  
1AB  
[dan@1abmedia.com](mailto:dan@1abmedia.com)